Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1.5% Butenyl ALA for Acne
NCT02313467Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of butenyl aminolevulinic acid in acne vulgaris (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Percent change of inflammatory acne lesions compared with baseline at 12 weeks. Started Jan 2014; status: completed.
02
Drugs
butenyl aminolevulinic acid
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02313467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313467.